Download pdf
The effectiveness and cost-effectiveness of digital therapeutics for prevention and management of hypertension
- 1 University College London, London, United Kingdom
* Author to whom correspondence should be addressed.
Abstract
Keywords
[1]. Hong, J. S., Wasden, C., & Han, D. H. (2021). Introduction of digital therapeutics. Computer Methods and Programs in Biomedicine, 209, 106319.
[2]. Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., & Chou, R. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Systematic Reviews, 10(1), 1-11.
[3]. Ponzo, S., Morelli, D., Kawadler, J. M., Hemmings, N. R., Bird, G., & Plans, D. (2020). Efficacy of the digital therapeutic mobile app Biobase to reduce stress and improve mental well-being among university students: Randomized controlled trial. JMIR mHealth and uHealth, 8(4), e17767.
[4]. Santiago-Torres, M., Mull, K. E., Sullivan, B. M., Kendzor, D. E., & Bricker, J. B. (2022). Efficacy and utilization of smartphone applications for smoking cessation among low-income adults: Secondary analysis of the iCanQuit randomized trial. Drug and Alcohol Dependence, 231, 109258.
[5]. Santiago-Torres, M., Mull, K. E., Sullivan, B. M., Kwon, D., Nollen, N. L., Zvolensky, M. J., & Bricker, J. B. (2021). Efficacy and utilization of an acceptance and commitment therapy-based smartphone application for smoking cessation among Black adults: Secondary analysis of the iCanQuit randomized trial. Addiction, 117(3), 760-771.
[6]. Santiago-Torres, M., Mull, K. E., Sullivan, B. M., Ferketich, A. K., & Bricker, J. B. (2022). Efficacy of an acceptance and commitment therapy-based smartphone application for helping rural populations quit smoking: Results from the iCanQuit randomized trial. Preventive Medicine, 157, 107008.
[7]. Santiago-Torres, M., Mull, K. E., Sullivan, B. M., Kwon, D. M., Nez Henderson, P., Nelson, L. A., Patten, C. A., & Bricker, J. B. (2021). Efficacy and utilization of smartphone applications for smoking cessation among American Indians and Alaska Natives: Results from the iCanQuit trial. Nicotine and Tobacco Research, 24(4), 544-554.
[8]. Kalmbach, D. A., Cheng, P., O'Brien, L. M., Swanson, L. M., Sangha, R., Sen, S., Guille, C., Cuamatzi-Castelan, A., Henry, A. L., Roth, T., & Drake, C. L. (2020). A randomized controlled trial of digital cognitive behavioral therapy for insomnia in pregnant women. Sleep Medicine, 72, 82-92.
[9]. Kario, K., Nomura, A., Harada, N., Okura, A., Nakagawa, K., Tanigawa, T., & Hida, E. (2021). Efficacy of a digital therapeutics system in the management of essential hypertension: The HERB-DH1 pivotal trial. European Heart Journal, 42(40), 4111-4122.
[10]. Kario, K., Nomura, A., Kato, A., Harada, N., Tanigawa, T., So, R., Suzuki, S., Hida, E., & Satake, K. (2021). Digital therapeutics for essential hypertension using a smartphone application: A randomized, open-label, multicenter pilot study. The Journal of Clinical Hypertension, 23(5), 923-934.
[11]. Li, Y., Gong, Y., Zheng, B., Fan, F., Yi, T., Zheng, Y., He, P., Fang, J., Jia, J., Zhu, Q., & Jiang, J. (2022). Effects on adherence to a mobile app-based self-management digital therapeutics among patients with coronary heart disease: Pilot randomized controlled trial. JMIR mHealth and uHealth, 10(2), e32251.
[12]. Luderer, H. F., Campbell, A. N., Nunes, E. V., Enman, N. M., Xiong, X., Gerwien, R., & Maricich, Y. A. (2022). Engagement patterns with a digital therapeutic for substance use disorders: Correlations with abstinence outcomes. Journal of Substance Abuse Treatment, 132, 108585.
[13]. Zill, J. M., Christalle, E., Meyer, B., Härter, M., & Dirmaier, J. (2019). The effectiveness of an internet intervention aimed at reducing alcohol consumption in adults: Results of a randomized controlled trial (Vorvida). Deutsches Ärzteblatt International, 116(8), 127.
[14]. Hwang, H., Kim, S. M., Netterstrøm, B., & Han, D. H. (2022). The efficacy of a smartphone-based app on stress reduction: Randomized controlled trial. Journal of Medical Internet Research, 24(2), e28703.
[15]. Morin, C. M. (2020). Profile of Somryst prescription digital therapeutic for chronic insomnia: Overview of safety and efficacy. Expert Review of Medical Devices, 17(12), 1239-1248.
[16]. Low, T., Conduit, R., Varma, P., Meaklim, H., & Jackson, M. L. (2020). Treating subclinical and clinical symptoms of insomnia with a mindfulness-based smartphone application: A pilot study. Internet Interventions, 21, 100335.
[17]. Freeman, D., Sheaves, B., Goodwin, G. M., Yu, L. M., Nickless, A., Harrison, P. J., Emsley, R., Luik, A. I., Foster, R. G., Wadekar, V., & Hinds, C. (2017). The effects of improving sleep on mental health (OASIS): A randomized controlled trial with mediation analysis. The Lancet Psychiatry, 4(10), 749-758.
[18]. Henry, A. L., Miller, C. B., Emsley, R., Sheaves, B., Freeman, D., Luik, A. I., Littlewood, D. L., Saunders, K. E., Kanady, J. C., Carl, J. R., & Davis, M. L. (2021). Insomnia as a mediating therapeutic target for depressive symptoms: A sub-analysis of participant data from two large randomized controlled trials of a digital sleep intervention. Journal of Sleep Research, 30(1), e13140.
[19]. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.
[20]. Espie, C. A., Emsley, R., Kyle, S. D., Gordon, C., Drake, C. L., Siriwardena, A. N., Cape, J., Ong, J. C., Sheaves, B., Foster, R., & Freeman, D. (2019). Effect of digital cognitive behavioral therapy for insomnia on health, psychological well-being, and sleep-related quality of life: A randomized clinical trial. JAMA Psychiatry, 76(1), 21-30.
[21]. Nomura, A., Tanigawa, T., Kario, K., & Igarashi, A. (2022). Cost-effectiveness of digital therapeutics for essential hypertension. medRxiv.
[22]. Nordyke, R. J., Appelbaum, K., & Berman, M. A. (2019). Estimating the impact of novel digital therapeutics in type 2 diabetes and hypertension: Health economic analysis. Journal of Medical Internet Research, 21(10), e15814.
[23]. Darden, M., Espie, C. A., Carl, J. R., Henry, A. L., Kanady, J. C., Krystal, A. D., & Miller, C. B. (2021). Cost-effectiveness of digital cognitive behavioral therapy (Sleepio) for insomnia: A Markov simulation model in the United States. Sleep, 44(4), zsaa223.
[24]. Mayo Clinic. (2021). Stress and high blood pressure: What's the connection? Retrieved from https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/in-depth/stress-and-high-blood-pressure/art-20044190
[25]. Husain, K., Ansari, R. A., & Ferder, L. (2014). Alcohol-induced hypertension: Mechanism and prevention. World Journal of Cardiology, 6(5), 245.
[26]. Deeks, J. J., Higgins, J. P. T., & Altman, D. G. (Eds.). (2022). Chapter 10: Analysing data and undertaking meta-analyses. In Cochrane Handbook for Systematic Reviews of Interventions (version 6.3). Cochrane.
[27]. U.S. Food and Drug Administration. (2020). What is digital health? Retrieved from https://www.fda.gov/medical-devices/digital-health-center-excellence/what-digital-health
[28]. Robinson, L. (2013). Is digital health technology empowering patients? Journal of Medical Radiation Sciences, 60(3), 79-80.
[29]. Chen, J., Mullins, C. D., Novak, P., & Thomas, S. B. (2016). Personalized strategies to activate and empower patients in health care and reduce health disparities. Health Education & Behavior, 43(1), 25-34.
Cite this article
Wang,Z. (2024). The effectiveness and cost-effectiveness of digital therapeutics for prevention and management of hypertension. Journal of Applied Economics and Policy Studies,14,1-5.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title:
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).